Replies to post #19499 on American Bio Medica Corp (fka ABMC)

[The Rainbow]

There are a few problems with this particular AYTU PR that will not work in the favor of what several posters are trying to accomplish with Melissa, but it sure works on shareholders. (However there are many other examples that are better). But this example is good for why to be cautious.

-These are not the Healgen Tests. AYTU was double dipping.

-The date: Friday, April 3, 2020 8:00 AM. is too early. Healgen FDA EUA was later at May 29

-Then the test in the article is only CE Rated:
This point-of-care test has been validated in a 126 patient clinical trial in China and is CE marked.

-I did this post: June 9
$ABMC COVID-19 Rapid Test outperforms the $AYTU partner- $CERC, Chembio Diagnostic Systems DPP Covid-19 IgM/IgG System test.

FDA Revokes Emergency Use Authorization for Chembio Antibody Test
https://www.prnewswire.com/news-releases/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-for-chembio-antibody-test-301078324.html

-Currently AYTU is working with a partner to develop an in house test.

The PR about AYTU "in house test" was great because now we know their plans.

And, CERC is actually moving higher on increasing volume at $2.74 So what did we learn? WE NEED PR'S ;-P